Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 2/7/2015 |
| Start Date: | October 2010 |
| End Date: | September 2012 |
| Contact: | Amber L. Bahorik, M.S.W. |
| Email: | bahorikal@upmc.edu |
| Phone: | 412-864-3807 |
This study will integrate and adapt a cognitive remediation (Cognitive Enhancement Therapy
[CET]) and an affect regulation (Personal Therapy [PT]) intervention for 50 individuals with
schizophrenia that misuse cannabis. Participants will be randomized to CET/PT plus treatment
as usual (TAU) or TAU alone and treated for 18 months.
[CET]) and an affect regulation (Personal Therapy [PT]) intervention for 50 individuals with
schizophrenia that misuse cannabis. Participants will be randomized to CET/PT plus treatment
as usual (TAU) or TAU alone and treated for 18 months.
Schizophrenia is a severe and chronic mental illness that places significant burden on the
individuals who suffer from it, their families, and society. One of the most vexing problems
in the treatment of schizophrenia is the high rate of substance use comorbidity. The
majority of schizophrenia patients experience substantial cognitive and affective
impairments. Consistent deficits have been observed in the broad domains of
neurocognition(e.g., attention, memory, and problem-solving), social cognition (e.g.,
perspective-taking, foresight, social cue recognition), and affect regulation, which are
major contributors to functional impairment in the disorder. These cognitive and affective
deficits may be exacerbated among schizophrenia patients that misuse substances and because
these deficits are untreated by current pharmacotherapeutic strategies many turn to cannabis
and other drugs to cope.
Cognitive Enhancement Therapy (CET) is a treatment that has proved effective in improving
cognition in individuals with schizophrenia. Personal Therapy (PT) is a treatment designed
to help individuals with the affective deficits that may lead to substance misuse for
individuals with schizophrenia. This study will adapt and integrate CET and PT to test
whether this intervention is better or more effective for treating substance misusing
schizophrenia patients than the usual treatment received (Treatment as Usual or TAU).
Participation in this study will last 18 months. Eligible participants will be randomly
assigned to receive either CET/PT or TAU. Participants that receive the CET/PT condition
must be able to attend weekly treatment sessions in Pittsburgh, PA. All participants will
complete cognitive, functional, and affective outcome measures at the beginning of the
study, 6-months, 12-months, and at 18-months regardless of treatment assignment. Results
from all outcome measures will be used to estimate the effectiveness of CET/PT for
individuals that have schizophrenia and misuse substances.
individuals who suffer from it, their families, and society. One of the most vexing problems
in the treatment of schizophrenia is the high rate of substance use comorbidity. The
majority of schizophrenia patients experience substantial cognitive and affective
impairments. Consistent deficits have been observed in the broad domains of
neurocognition(e.g., attention, memory, and problem-solving), social cognition (e.g.,
perspective-taking, foresight, social cue recognition), and affect regulation, which are
major contributors to functional impairment in the disorder. These cognitive and affective
deficits may be exacerbated among schizophrenia patients that misuse substances and because
these deficits are untreated by current pharmacotherapeutic strategies many turn to cannabis
and other drugs to cope.
Cognitive Enhancement Therapy (CET) is a treatment that has proved effective in improving
cognition in individuals with schizophrenia. Personal Therapy (PT) is a treatment designed
to help individuals with the affective deficits that may lead to substance misuse for
individuals with schizophrenia. This study will adapt and integrate CET and PT to test
whether this intervention is better or more effective for treating substance misusing
schizophrenia patients than the usual treatment received (Treatment as Usual or TAU).
Participation in this study will last 18 months. Eligible participants will be randomly
assigned to receive either CET/PT or TAU. Participants that receive the CET/PT condition
must be able to attend weekly treatment sessions in Pittsburgh, PA. All participants will
complete cognitive, functional, and affective outcome measures at the beginning of the
study, 6-months, 12-months, and at 18-months regardless of treatment assignment. Results
from all outcome measures will be used to estimate the effectiveness of CET/PT for
individuals that have schizophrenia and misuse substances.
Inclusion Criteria:
- Diagnosis of schizophrenia or schizoaffective disorder confirmed by the Structured
Clinical Interview for DSM-IV Disorders (SCID).
- Cannabis severity scores of moderate or higher on the Addiction Severity Index (ASI).
- present with significant cognitive disability based on the Cognitive Style and Social
Cognition Eligibility Interview
- Intelligence quotient (IQ) greater than 80
- Ability to read and speak fluent English
- Ability to attend weekly treatment sessions in Pittsburgh, PA.
Exclusion Criteria:
- Organic Brain Syndrome
- English Language below a sixth grade level
- Persistent suicidal or homicidal behavior
- comorbid medical disorders producing cognitive impairment
- receipt of substance abuse pharmacotherapies (e.g., naltrexone)
We found this trial at
1
site
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Click here to add this to my saved trials
